169 related articles for article (PubMed ID: 38380360)
1. Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy.
Li F; Wang Y; Dou H; Chen X; Wang J; Xiao M
Front Oncol; 2024; 14():1349021. PubMed ID: 38380360
[TBL] [Abstract][Full Text] [Related]
2. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Truffi M; Sottotetti F; Gafni N; Albasini S; Piccotti F; Morasso C; Tibollo V; Mocchi M; Zanella V; Corsi F
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358706
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
5. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients.
Jin X; Wang K; Shao X; Huang J
Gland Surg; 2022 Jun; 11(6):1057-1066. PubMed ID: 35800742
[TBL] [Abstract][Full Text] [Related]
8. Correlation between inflammatory markers over time and disease severity in status epilepticus: a preliminary study.
Shi X; Zhang X; Song S; Pan H; Huang C; Sun T; Wang S; Xu J
Front Neurol; 2024; 15():1334415. PubMed ID: 38370523
[TBL] [Abstract][Full Text] [Related]
9. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
[TBL] [Abstract][Full Text] [Related]
10. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey.
Acikgoz O; Yildiz A; Bilici A; Olmez OF; Basim P; Cakir A
Anticancer Drugs; 2022 Nov; 33(10):1150-1155. PubMed ID: 36206103
[TBL] [Abstract][Full Text] [Related]
12. Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.
Gasparri ML; Albasini S; Truffi M; Favilla K; Tagliaferri B; Piccotti F; Bossi D; Armatura G; Calcinotto A; Chiappa C; Combi F; Curcio A; Della Valle A; Ferrari G; Folli S; Ghilli M; Listorti C; Mancini S; Marinello P; Mele S; Pertusati A; Roncella M; Rossi L; Rovera F; Segattini S; Sgarella A; Tognali D; Corsi F
Ther Adv Med Oncol; 2023; 15():17588359231193732. PubMed ID: 37720495
[TBL] [Abstract][Full Text] [Related]
13. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer.
Yang G; Liu P; Zheng L; Zeng J
Front Surg; 2022; 9():1004687. PubMed ID: 36406359
[TBL] [Abstract][Full Text] [Related]
14. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727
[TBL] [Abstract][Full Text] [Related]
15. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
16. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
Front Oncol; 2021; 11():678315. PubMed ID: 34367964
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL.
Zhu M; Zhou Y; Liu Z; Jiang Z; Qi W; Chen S; Wang W; Shi B; Zhu Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769469
[TBL] [Abstract][Full Text] [Related]
18. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
[TBL] [Abstract][Full Text] [Related]
20. Pan-immune-inflammation value: a new prognostic index in operative laryngeal and pharyngeal carcinomas.
Shi J; Liu C; Yang N; Qiu C
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38877363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
